Heading structure used in this document: one H1, fifteen H2 sections (numbered 1 to 15) and H3 sub-sections where needed. Citations in square brackets point to the numbered reference list in section 15.

Saffron Human Clinical Research: What the Evidence Shows

1. Executive Evidence Summary

Saffron (Crocus sativus L.) has been studied in dozens of randomised controlled trials in people, most of them using standardised stigma extracts taken as capsules at roughly 20 to 30 mg a day. The research is concentrated in mental health, but it also covers premenstrual symptoms, sexual function, cognition, eye health, appetite and metabolic markers [1,3,4,25].

In brief, the human evidence says the following:

•       Depression has the largest body of evidence. Meta-analyses of short trials report that saffron outperformed placebo and performed similarly to some antidepressants [1,2,3].

•       Anxiety, stress and sleep show encouraging results in smaller trials, with less consistent findings [3,10,11,12,13].

•       Premenstrual symptoms and antidepressant-related sexual dysfunction improved in a few small placebo-controlled studies [14,16,17].

•       Alzheimer's disease trials found saffron comparable to donepezil or memantine, but these studies were small [18,19,20].

•       Early macular degeneration studies reported better retinal function in small groups [21,22].

•       Appetite and metabolic health results are early and inconsistent [23,25].

Taken together, the evidence is promising but of low to moderate certainty. The trials are mostly small, short and clustered among a limited number of research groups. Saffron should not be seen as a proven replacement for standard medical treatment, and this article explains why.

2. Saffron Forms, Doses and Study Designs Used in Trials

Clinical results only make sense when you know what was actually given to participants. Published trials have used several different saffron products, and these are not interchangeable.

Forms of saffron

The most common form is a hydro-alcoholic or aqueous extract of the stigma, delivered in capsules. Some trials used petal extract, which has a different chemical profile and costs far less to produce [8]. Others used branded, standardised extracts such as affron and Satiereal, which are tested for marker compounds like crocins and safranal [10,23]. Culinary saffron has rarely been tested in a controlled way, so trial results cannot be projected onto cooking amounts.

Doses and duration

The typical dose in mood, premenstrual and Alzheimer's trials was 30 mg of extract per day, often split into two 15 mg doses [6,7,14,18]. Some standardised extracts were tested at about 28 mg a day, and eye studies used 20 mg a day [10,12,21]. A weight-management study used a higher dose of about 176 mg a day of a specific extract [23]. Trial length ranged from four weeks to one year, with most lasting six to twelve weeks.

Study designs

Three designs account for most of the literature. Placebo-controlled trials compare saffron with an inactive capsule. Active-comparator trials compare it with a drug such as fluoxetine, donepezil or memantine. A few studies use crossover or add-on designs, where saffron is given on top of existing treatment. The distinction matters because a trial that shows saffron is "as good as" a drug, without a placebo group, cannot prove that either treatment worked better than no treatment. Placebo responses in mood studies are often large.

Outcome measures

Trials do not all measure the same thing. Depression studies mostly used clinician-rated scales such as the Hamilton Depression Rating Scale, or self-rated tools such as the Beck Depression Inventory. Alzheimer's trials relied on cognitive and global scales such as ADAS-Cog and the Clinical Dementia Rating. Sleep studies used questionnaires on sleep quality and insomnia severity, and the AMD trials used electroretinography to record macular function. Each scale has its own meaning for patients, so a "significant" change on one scale cannot be compared directly with a change on another.

3. How to Read Clinical Evidence

Not all human studies carry the same weight. Systematic reviews and meta-analyses of randomised trials sit at the top of the evidence hierarchy, followed by individual randomised controlled trials, then observational studies, then case reports. Laboratory and animal work, which explains plausible mechanisms, comes lower still because it cannot show benefit in patients.

Several concepts help when judging any saffron study:

•       Randomisation and blinding. Random assignment limits selection bias, and blinding reduces expectation effects. Saffron's strong colour and aroma can make blinding imperfect.

•       Sample size. Most saffron trials enrol 25 to 100 people, which makes results unstable and easy to overstate.

•       Clinical versus statistical significance. A difference can be statistically significant yet too small to matter to a patient.

•       Surrogate versus clinical outcomes. A change in a blood marker is not the same as a better quality of life.

•       Heterogeneity and publication bias. When trial results vary widely, or negative studies go unpublished, pooled estimates can look better than reality.

4. Depression

Depression is the best-studied indication. The first placebo-controlled trial, in 40 adults with mild to moderate depression, found that 30 mg of saffron extract daily for six weeks produced greater symptom improvement than placebo [6]. A pilot study of similar size and length found that saffron extract performed comparably to 20 mg of fluoxetine on a standard depression scale [7]. A trial with petal extract against fluoxetine reported a similar pattern [8], and a study in people recovering from a heart procedure also reported comparable results to fluoxetine [9].

Meta-analyses have pooled these and later trials. An early meta-analysis of randomised trials reported a large benefit of saffron over placebo and no clear difference from antidepressants in the short term [1]. A later meta-analysis restricted to mild to moderate depression reached a similar conclusion [2], and a broader review covering depression and anxiety found significant improvement in both [3]. Wider reviews of psychological outcomes agree in direction but stress the limitations [4,5].

Reading the "comparable to fluoxetine" claim

Headlines often say that saffron works "as well as" an antidepressant. In the underlying trials this usually means that the average score change in the saffron group was not statistically different from the drug group after six to eight weeks, in samples of around 40 people. A study that small can easily miss a real difference between two treatments, so "no difference found" is not the same as "equally effective". The finding is a reason for larger comparisons, not evidence that saffron can substitute for a prescribed drug.

Why caution is still needed

The pooled effect sizes are unusually large for a supplement, which should itself prompt scepticism. Many of the trials were small and short, a disproportionate share came from a few research groups, and several did not describe randomisation or blinding in detail. Most enrolled people with mild to moderate symptoms, so the findings say little about severe depression, suicidality or long-term relapse prevention. Active-comparator trials did not include placebo groups that would show whether either treatment truly worked in that sample. Saffron should not be used to replace prescribed antidepressants without medical supervision.

5. Anxiety, Stress and Sleep

Anxiety and mood

Reviews of saffron for anxiety report smaller and less consistent benefits than for depression, partly because fewer trials measured anxiety as a primary outcome [3,4]. In a trial of adolescents with mild anxiety and depressive symptoms, a standardised extract improved scores relative to placebo, although the study was small [10]. In healthy adults reporting low mood, four weeks of a standardised extract improved mood scores compared with placebo [11]. These studies suggest an effect on subjective mood and stress, which is not the same as treating an anxiety disorder.

Sleep

Two randomised trials in adults with poor or disturbed sleep reported better self-reported sleep quality with a standardised saffron extract than with placebo [12,13]. The effects were measured with questionnaires, and both trials were short and modest in size. Objective sleep measures, such as polysomnography, are lacking, so it is unclear whether saffron changes sleep architecture or mainly how rested people feel. Participants were also generally healthy adults with self-reported poor sleep, not patients with diagnosed insomnia, so the findings may not extend to clinical sleep disorders.

Overall, the evidence for anxiety, stress and sleep is early. It is consistent enough to justify larger trials with objective outcomes, but not strong enough to support firm claims.

6. Premenstrual Symptoms and Sexual Function

Premenstrual syndrome

In a double-blind trial of 50 women with premenstrual syndrome, 30 mg of saffron a day over two menstrual cycles reduced symptom scores more than placebo [14]. A separate small study found that inhaling saffron aroma reduced anxiety and cortisol in women during the luteal phase of the cycle [15]. Both results are interesting, but one randomised trial with a small sample cannot be considered definitive. The aroma study also measured a short-term response, so it says little about everyday symptom relief. Independent replication, ideally with larger groups and several menstrual cycles of follow-up, is needed.

Antidepressant-related sexual dysfunction

Sexual side effects are a common reason people stop taking antidepressants. In a four-week trial of men taking fluoxetine, saffron improved erectile function and intercourse satisfaction compared with placebo, without clear benefit across other sexual domains [16]. A parallel trial in women taking fluoxetine reported improvements in arousal and lubrication, but not in pain or desire-related measures [17]. Samples were under 40 participants per study, and the results apply to a specific situation: people already on fluoxetine. They should not be assumed to apply to sexual dysfunction in general.

7. Cognition and Alzheimer's Disease

Alzheimer's disease is the second major area of human research. In a 16-week placebo-controlled trial in 46 people with mild to moderate disease, 30 mg of saffron daily produced better cognitive scores than placebo [18]. A 22-week trial in 54 patients compared saffron with donepezil and found similar cognitive outcomes, with fewer cases of vomiting in the saffron group [19]. A year-long trial in 68 people with moderate to severe disease compared saffron with memantine and also reported comparable results [20].

How to interpret these findings

These are small studies run by a closely related group of investigators. The comparisons with donepezil and memantine are non-inferiority style designs, and similar results between two groups do not prove that either one works better than doing nothing. Mild to moderate Alzheimer's disease also progresses slowly, so the trial lengths limit what can be concluded about disease modification.

What the trials do show is that saffron was tolerated in older adults with dementia and that cognitive scores did not worsen relative to established drugs over the study periods. They do not show that saffron slows disease progression, protects the brain, or prevents dementia in healthy people. Evidence on cognition in cognitively healthy adults is much thinner.

8. Eye Health and Age-Related Macular Degeneration

Age-related macular degeneration (AMD) damages central vision. The saffron research here is led by a small number of studies. In a crossover trial of 25 people with early AMD, 20 mg of saffron daily for three months improved retinal flicker sensitivity, a measure of macular function [21]. A follow-up study of 29 patients over about 14 months reported that the benefit on central retinal function was maintained during continued supplementation [22].

These findings are interesting because retinal function was measured objectively. However, the samples were small, the main outcome was a laboratory measure rather than everyday vision, and no study has shown that saffron prevents vision loss or progression to advanced AMD. Established strategies for AMD, such as specific nutrient formulas, smoking cessation and regular eye examinations, remain the standard, and saffron should be regarded as experimental.

9. Appetite, Weight and Metabolic Health

Appetite and snacking

In an eight-week placebo-controlled study of 60 mildly overweight women, a saffron extract reduced snacking frequency and increased satiety ratings, with a trend toward weight loss that was small [23]. Because appetite is influenced by mood and stress, a mood-related mechanism has been proposed, but this was not tested directly. The weight change was small, and a short study of this kind cannot show whether the effect lasts or whether it matters for long-term health.

Glucose, lipids and body weight

Trials in people with diabetes, prediabetes or metabolic syndrome have examined blood glucose, cholesterol, blood pressure and body weight. Results vary by population, dose and product, and pooled analyses show high heterogeneity [25]. Some trials report small improvements in selected markers, while others find no difference from placebo. The overall picture is that metabolic effects are possible but unproven, and saffron cannot be considered a substitute for diet, exercise or medication.

10. Evidence at a Glance

The table summarises typical trial conditions and findings. The final column is a qualitative judgement of how certain the evidence is, based on trial size, design and consistency, and not a formal grading.

Area	Typical dose and length	Main finding	Evidence certainty
Depression	About 30 mg/day for 6 to 8 weeks	Better than placebo; similar to some antidepressants in small trials	Low to moderate
Anxiety and mood	14 to 30 mg/day for 4 to 12 weeks	Some improvement in anxiety and mood scores	Low to moderate
Sleep	About 28 to 30 mg/day for about 4 weeks	Better self-reported sleep quality	Low
Premenstrual syndrome	30 mg/day for 2 cycles	Lower symptom scores than placebo	Low
SSRI-related sexual dysfunction	30 mg/day for 4 weeks	Improved some domains in men and women	Low
Alzheimer's disease	30 mg/day for 16 to 52 weeks	Cognitive scores similar to donepezil or memantine	Low
Early AMD	20 mg/day for 3 to 14 months	Improved retinal flicker sensitivity	Low
Appetite and snacking	About 176 mg/day for 8 weeks	Less snacking, more satiety	Low
Glucose and lipids	Varied	Inconsistent results	Very low to low

 

11. Safety, Tolerability and Interactions

At the doses used in most trials, saffron has been generally well tolerated. Reported side effects were usually mild and included nausea, headache, dry mouth, dizziness and changes in appetite, and they occurred at similar rates to placebo in many studies [3,25]. A safety study in healthy volunteers who took 200 to 400 mg a day for a week found no serious adverse effects, though some laboratory values shifted slightly [24].

Safety is not unlimited. Very large amounts, in the range of several grams, are considered toxic, and high intakes are avoided during pregnancy because of possible uterine stimulation [25]. Long-term safety data beyond about one year are limited, and no large trial has been designed with safety as the primary outcome.

Who should be careful

•       People taking antidepressants or other psychiatric medication. Saffron may influence serotonin signaling and mood, and trial participants were closely monitored.

•       People with bipolar disorder. Any mood-active ingredient may carry a risk of triggering mania, and data in this group are lacking.

•       People taking blood thinners or with bleeding disorders. Interaction data are limited, so medical advice is sensible.

•       Pregnant or breastfeeding women. Supplement doses should be discussed with a clinician.

•       Anyone with a known allergy to saffron or related plants, such as Crocus species.

Product quality adds another variable. Saffron is among the most commonly adulterated spices, and supplements vary in standardisation. Results from a trial of a given extract cannot be assumed for a different brand.

12. Quality and Limitations of the Evidence

When these limitations are laid out together, the reason for a cautious verdict becomes clear.

•       Small samples. Individual trials usually enrol fewer than 100 people, so effect sizes are imprecise and prone to inflation.

•       Short duration. Most trials last under three months, which limits conclusions on long-term benefit, relapse and safety.

•       Concentration of research groups. A large share of trials come from a limited number of teams, so independent replication is limited.

•       Risk of bias. Several trials give limited detail on randomisation, blinding and dropouts. Saffron's colour and smell make blinding harder.

•       Heterogeneity. Products, doses, populations and outcome scales differ, so pooled results can hide important differences.

•       Publication and funding bias. Positive trials are more likely to be published, and some standardised extracts were tested in studies connected to their manufacturers.

•       Surrogate outcomes. Several studies use questionnaires or laboratory markers rather than outcomes such as function, relapse or hospitalisation.

Another point is that effect sizes reported in small trials tend to shrink when larger, more rigorous studies are run. This pattern is well documented across medicine, and it is a reasonable expectation here too. A realistic reading is that saffron may offer a modest benefit for some people, not the large effects that some pooled estimates suggest.

None of these limitations means saffron does not work. They mean that the size of the benefit is uncertain, probably smaller than headline meta-analyses imply, and that the strongest claim the evidence supports is "promising".

13. Human Relevance

How should a reader apply this evidence? First, the results are most relevant to adults with mild to moderate symptoms, using a standardised extract at studied doses for a limited period. They do not clearly apply to severe illness, to children and adolescents beyond the small trial cited, or to culinary use.

Second, the findings fit a plausible biological story. Laboratory work suggests that crocins, crocetin and safranal may influence monoamine signaling, glutamate transmission, oxidative stress and inflammation [26,27]. This helps explain why mood, cognition and retinal function were studied, but it does not confirm that those mechanisms drove the clinical effects, since almost no trial measured mechanistic biomarkers.

Regulatory status is also worth knowing. In most jurisdictions saffron extract is sold as a dietary supplement and is not approved as a treatment for depression, dementia or any other condition, so manufacturers cannot claim to treat disease. Quality control, labelling accuracy and dose consistency therefore depend heavily on the manufacturer, and third-party testing is a useful signal when choosing a product.

Third, saffron is best framed as a possible complementary option and not as an alternative to evidence-based care. For depression, anxiety, dementia and eye disease, established treatments have larger and better-documented evidence, and delaying them carries real risk. Anyone considering saffron alongside medication should speak with a doctor or pharmacist, choose a standardised product from a reputable manufacturer, and track symptoms so that the response can be judged.

Common reader questions

Does cooking with saffron count? Trials used measured extract doses, so culinary use has not been shown to produce the same effects. Using it in food is generally considered safe in normal amounts, but it should not be treated as a therapeutic dose.

How long did it take to see an effect? Trials that reported benefits usually measured them after four to eight weeks, so any response should be judged over a similar period. A lack of change over that time is useful information to share with a clinician.

Can it be used with medication? This depends on the medication and the person. Because saffron may influence mood-related signaling, a pharmacist or doctor should review any combination before starting.

14. Evidence Gaps and Uncertainty

The most useful next steps for researchers are fairly clear:

•       Larger, independent, pre-registered trials with adequate sample sizes and rigorous blinding.

•       Longer follow-up, ideally six to twelve months, with relapse and safety as outcomes.

•       Objective measures, such as polysomnography for sleep, imaging for cognition and biomarkers for inflammation and BDNF.

•       Head-to-head comparisons of whole extracts and individual compounds, and of different standardisation levels.

•       Pharmacokinetic studies in humans to confirm what reaches the blood and brain after oral dosing [27].

•       Trials in diverse populations, including older adults, people with comorbidities and groups outside the regions where most studies have been done.

Until those studies exist, the honest summary is this: human trials of saffron are consistently positive in direction, but small, short and at risk of bias, so the certainty of benefit is low to moderate. The strongest case is for mild to moderate depression and the weakest is for metabolic outcomes.

This article is for educational purposes and is not medical advice. Speak to a qualified healthcare professional before using saffron supplements, especially if you are pregnant, have a medical condition or take prescription medication.

15. References

[1]  Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J Integr Med. 2013;11(6):377-383.

[2]  Tóth B, Hegyi P, Lantos T, et al. The efficacy of saffron in the treatment of mild to moderate depression: a meta-analysis. Planta Med. 2019;85(1):24-31.

[3]  Marx W, Lane M, Rocks T, et al. Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. Nutr Rev. 2019;77(8):557-571.

[4]  Shafiee M, Arekhi S, Omranzadeh A, Sahebkar A. Saffron in the treatment of depression, anxiety and other mental disorders: current evidence and potential mechanisms of action. J Affect Disord. 2018;227:330-337.

[5]  Hausenblas HA, Heekin K, Mutchie HL, Anton S. A systematic review of randomized controlled trials examining the effectiveness of saffron (Crocus sativus L.) on psychological and behavioral outcomes. J Integr Med. 2015;13(4):231-240.

[6]  Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, et al. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytother Res. 2005;19(2):148-151.

[7]  Noorbala AA, Akhondzadeh S, Tamacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J Ethnopharmacol. 2005;97(2):281-284.

[8]  Akhondzadeh Basti A, Moshiri E, Noorbala AA, et al. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):439-442.

[9]  Shahmansouri N, Farokhnia M, Abbasi SH, et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. J Affect Disord. 2014;155:216-222.

[10]  Lopresti AL, Drummond PD, Inarejos-García AM, Prodanov M. affron®, a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: a randomised, double-blind, placebo-controlled study. J Affect Disord. 2018;232:349-357.

[11]  Kell G, Rao A, Beccaria G, et al. affron® a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial. Complement Ther Med. 2017;33:58-64.

[12]  Lopresti AL, Smith SJ, Metse AP, Drummond PD. Effects of saffron on sleep quality in healthy adults with self-reported poor sleep: a randomized, double-blind, placebo-controlled trial. J Clin Sleep Med. 2020;16(6):937-947.

[13]  Pachikian BD, Copine S, Suchareau M, Deldicque L. Effects of saffron extract on sleep quality: a randomized double-blind controlled clinical trial. Nutrients. 2021;13(5):1473.

[14]  Agha-Hosseini M, Kashani L, Aleyaseen A, et al. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG. 2008;115(4):515-519.

[15]  Fukui H, Toyoshima K, Komaki R. Psychological and neuroendocrinological effects of odor of saffron (Crocus sativus). Phytomedicine. 2011;18(8-9):726-730.

[16]  Modabbernia A, Sohrabi H, Nasehi AA, et al. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology. 2012;223(4):381-388.

[17]  Kashani L, Raisi F, Saroukhani S, et al. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Hum Psychopharmacol. 2013;28(1):54-60.

[18]  Akhondzadeh S, Sabet MS, Harirchian MH, et al. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. J Clin Pharm Ther. 2010;35(5):581-588.

[19]  Akhondzadeh S, Shafiee Sabet M, Harirchian MH, et al. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease. Psychopharmacology. 2010;207(4):637-643.

[20]  Farokhnia M, Shafiee Sabet M, Iranpour N, et al. Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial. Hum Psychopharmacol. 2014;29(4):351-359.

[21]  Falsini B, Piccardi M, Minnella A, et al. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51(12):6118-6124.

[22]  Piccardi M, Marangoni D, Minnella AM, et al. A longitudinal follow-up study of saffron supplementation in early age-related macular degeneration: sustained benefits to central retinal function. Evid Based Complement Alternat Med. 2012;2012:429124.

[23]  Gout B, Bourges C, Paineau-Dubreuil S. Satiereal, a Crocus sativus L extract, reduces snacking and increases satiety in a randomized placebo-controlled study of mildly overweight, healthy women. Nutr Res. 2010;30(5):305-313.

[24]  Modaghegh MH, Shahabian M, Esmaeili HA, Rajbai O, Hosseinzadeh H. Safety evaluation of saffron (Crocus sativus) tablets in healthy volunteers. Phytomedicine. 2008;15(12):1032-1037.

[25]  Moshiri M, Vahabzadeh M, Hosseinzadeh H. Clinical applications of saffron (Crocus sativus) and its constituents: a review. Drug Res. 2015;65(6):287-295.

[26]  Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Hum Psychopharmacol. 2014;29(6):517-527.

[27]  Asai A, Nakano T, Takahashi M, Nagao A. Orally administered crocetin and crocins are absorbed into blood plasma as crocetin and its glucuronide conjugates in mice. J Agric Food Chem.